Literature DB >> 1787650

Elevated urinary excretion of the C5b-9 complex in membranous nephropathy.

M Schulze1, J V Donadio, C J Pruchno, P J Baker, R J Johnson, R A Stahl, S Watkins, D C Martin, R Wurzner, O Gotze.   

Abstract

In experimental membranous nephropathy, antibody binding to glomerular epithelial cell membrane antigens results in complement activation and formation of complement C5b-9 membrane attack complexes in glomeruli. During active disease, the C5b-9 complexes are shed into the urine. To test the hypothesis that a similar mechanism might be operative in human membranous nephropathy, we measured urinary excretion of C5b-9 and C5 in 146 proteinuric patients with biopsy-proven glomerular diseases or diabetes mellitus. Urinary excretion of C5b-9 relative to C5 excretion was higher in 40 patients with membranous nephropathy than in 106 patients with proteinuria due to non-membranous glomerulonephritis when analyzed by covariance analysis (P less than 0.0002). Urinary C5b-9 excretion was higher in membranous nephropathy than in membranoproliferative glomerulonephritis (N = 13, P less than 0.05), minimal change-focal sclerosis (N = 33, P less than 0.001), mesangial proliferative glomerulonephritis (N = 9, P less than 0.02) and IgA nephropathy (N = 7, P less than 0.025). Urinary C5b-9 excretion was also higher in patients with lupus nephritis (N = 18, P less than 0.02) compared to those with non-membranous glomerulonephritis. The lupus patients with the highest excretion had clinical or pathological features of membranous nephropathy. Nine patients with membranous nephropathy and elevated urinary C5b-9 excretion had a shorter duration of disease (P less than 0.05), lower serum creatinine levels (P less than 0.05) and more proteinuria (P less than 0.02) than the 31 membranous nephropathy patients with normal values.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1787650     DOI: 10.1038/ki.1991.242

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

Review 1.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

Review 2.  Complement activation in progressive renal disease.

Authors:  Amy Fearn; Neil Stephen Sheerin
Journal:  World J Nephrol       Date:  2015-02-06

Review 3.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

Review 4.  Membranous nephropathy. Insights from Heymann nephritis.

Authors:  T Cavallo
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

Review 5.  Unmet challenges in membranous nephropathy.

Authors:  David J Salant
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-01       Impact factor: 2.894

Review 6.  [Membranous glomerulonephritis].

Authors:  S Scheidat; R A K Stahl
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

7.  Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease).

Authors:  J H Jansen; K Høgåsen; T E Mollnes
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

Review 8.  The role of complement in membranous nephropathy.

Authors:  Hong Ma; Dana G Sandor; Laurence H Beck
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

9.  Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis.

Authors:  M Schulze; C J Pruchno; M Burns; P J Baker; R J Johnson; W G Couser
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

10.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.